In Dr Hussain’s case, two prominent gynecologic oncologists suggested hospice without mentioning avutometinib plus defactinib. Banerjee notes the FDA accelerated approval and NCCN listing are over a year old and calls for multi-prong education for all clinicians across the clinical oncology team, much like the BRCA/PARP rollout.
Banerjee was surprised the patient got benefit from pelvic radiation, but at Royal Marsden she has seen radiotherapy work less well in LGSOC than in high-grade ovarian cancer. She would consider it for focal lesions when options are limited, while weighing toxicity and trial access.
Banerjee uses weekly paclitaxel as later-line LGSOC therapy, especially when subacute bowel obstruction makes oral MEK inhibitor absorption risky, and has seen responses. If bevacizumab is not contraindicated, she would pair it with weekly paclitaxel, citing bevacizumab activity reports, and might add pembrolizumab if available.
Banerjee notes FDA interest in echocardiograms with MEK inhibitors, and RAMP 301 introduced them. Even an asymptomatic patient doing well should get an echo, she says, because cardiac dysfunction can be managed by pausing the drug, treating with cardiology input, and restarting when ejection fraction improves.
Banerjee says a patient from her phase 1 study stayed on avutometinib plus defactinib for about five years, showing durable efficacy and tolerability. She stresses it is active treatment rather than maintenance and would continue it in her practice until progression unless side effects limit tolerability.
Banerjee has not told patients to avoid exercise and has not seen symptomatic muscle or cardiac events from CPK elevation. She manages it by grade in her practice: pause grade 3 until recovery, then resume the same dose; grade 4 may require dose reduction or stopping.
Banerjee says with a KRAS mutation at progression she would likely choose avutometinib plus defactinib in the US, but for KRAS wild-type disease she would try trametinib or binimetinib first. She considers folate-receptor ADC evidence in LGSOC still anecdotal and reserves mirvetuximab after MEK/RAF therapy.
